

## Correction to: Ibalizumab: First Global Approval

Anthony Markham<sup>1</sup>

Published online: 30 May 2018  
© Springer Nature 2018

**Correction to: Drugs 78(7):781–785 (2018)**  
<https://doi.org/10.1007/s40265-018-0907-5>

The article Ibalizumab: First Global Approval, written by Anthony Markham, was originally published Online First without open access. After publication in volume 78, issue 7, pages 781–785 Theratechnologies Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Theratechnologies Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits

any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article was corrected.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

---

The original article can be found online at <https://doi.org/10.1007/s40265-018-0907-5>.

---

✉ Anthony Markham  
dru@adis.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand